{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:31:47Z","timestamp":1758630707775},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,6]]},"DOI":"10.7759\/cureus.55652","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T15:18:20Z","timestamp":1709738300000},"source":"Crossref","is-referenced-by-count":1,"title":["Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Case Report"],"prefix":"10.7759","author":[{"given":"Smaran  S","family":"Teru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaswanthi","family":"Dogiparthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J","family":"Bonitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Buzas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi E","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, et al.. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022, 13:885218. 10.3389\/fneur.2022.885218","journal-title":"Front Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032986","article-title":"Pediatric myelin oligodendrocyte glycoprotein antibody associated disease-asymmetric papilledema and elevated ICP are two of the chameleons: a case report","volume":"102","author":"Alqahtani Y","year":"2023","unstructured":"Alqahtani Y, Oshi M, Kamal NM, Aljabri M, Abosabie S, Elhaj W, Abosabie SA. Pediatric myelin oligodendrocyte glycoprotein antibody associated disease-asymmetric papilledema and elevated ICP are two of the chameleons: a case report. Medicine (Baltimore). 2023, 102:e32986. 10.1097\/MD.0000000000032986","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan S","year":"2016","unstructured":"Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016, 15:307-24. 10.1016\/j.autrev.2015.12.004","journal-title":"Autoimmun Rev"},{"key":"ref4","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): clinical features and diagnosis","author":"Flanagan EP","year":"2024","unstructured":"Flanagan EP, Tillema JM. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): clinical features and diagnosis. UpToDate. Post TW (ed): UpToDate, Waltham, MA; 2024."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro M","year":"2018","unstructured":"Spadaro M, Winklmeier S, Beltr\u00e1n E, et al.. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol. 2018, 84:315-28. 10.1002\/ana.25291","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor KC","year":"2007","unstructured":"O'Connor KC, McLaughlin KA, De Jager PL, et al.. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007, 13:211-7. 10.1038\/nm1488","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell K","year":"2020","unstructured":"O'Connell K, Hamilton-Shield A, Woodhall M, et al.. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry. 2020, 91:1126-8. 10.1136\/jnnp-2020-323158","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol CL","year":"2020","unstructured":"de Mol CL, Wong Y, van Pelt ED, et al.. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020, 26:806-14. 10.1177\/1352458519845112","journal-title":"Mult Scler"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk M","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, et al.. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017, 140:3128-38. 10.1093\/brain\/awx276","journal-title":"Brain"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan S","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, et al.. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018, 89:127-37. 10.1136\/jnnp-2017-316880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo A","year":"2021","unstructured":"Cobo-Calvo A, Ruiz A, Rollot F, et al.. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol. 2021, 89:30-41. 10.1002\/ana.25909","journal-title":"Ann Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen JJ","year":"2020","unstructured":"Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020, 33:47-54. 10.1097\/WCO.0000000000000766","journal-title":"Curr Opin Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen JJ","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J, et al.. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018, 195:8-15. 10.1016\/j.ajo.2018.07.020","journal-title":"Am J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000224757.69746.fb","article-title":"The clinical features, MRI findings, and outcome of optic neuritis in children","volume":"67","author":"Wilejto M","year":"2006","unstructured":"Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology. 2006, 67:258-62. 10.1212\/01.wnl.0000224757.69746.fb","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200020","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as intracranial hypertension: a case report","volume":"9","author":"Chaudhuri JR","year":"2022","unstructured":"Chaudhuri JR, Bagul JJ, Swathi A, Singhal BS, Reddy NC, Vallam KK. Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as intracranial hypertension: a case report. Neurol Neuroimmunol Neuroinflamm. 2022, 9:e200020. 10.1212\/NXI.0000000000200020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp LB","year":"2013","unstructured":"Krupp LB, Tardieu M, Amato MP, et al.. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013, 19:1261-7. 10.1177\/1352458513484547","journal-title":"Mult Scler"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue T","year":"2020","unstructured":"Armangue T, Oliv\u00e9-Cirera G, Mart\u00ednez-Hernandez E, et al.. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020, 19:234-46. 10.1016\/S1474-4422(19)30488-0","journal-title":"Lancet Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey D","year":"2019","unstructured":"Dubey D, Pittock SJ, Krecke KN, et al.. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019, 76:301-9. 10.1001\/jamaneurol.2018.4053","journal-title":"JAMA Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease","volume":"2","author":"Mariano R","year":"2019","unstructured":"Mariano R, Messina S, Kumar K, Kuker W, Leite MI, Palace J. Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease. JAMA Netw Open. 2019, 2:e1912732. 10.1001\/jamanetworkopen.2019.12732","journal-title":"JAMA Netw Open"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519849511","article-title":"Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: a retrospective multicentric study","volume":"26","author":"Ciron J","year":"2020","unstructured":"Ciron J, Cobo-Calvo A, Audoin B, et al.. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: a retrospective multicentric study. Mult Scler. 2020, 26:936-44. 10.1177\/1352458519849511","journal-title":"Mult Scler"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000900","article-title":"Myelitis and other autoimmune myelopathies","volume":"27","author":"Lopez Chiriboga S","year":"2021","unstructured":"Lopez Chiriboga S, Flanagan EP. Myelitis and other autoimmune myelopathies. Continuum (Minneap Minn). 2021, 27:62-92. 10.1212\/CON.0000000000000900","journal-title":"Continuum (Minneap Minn)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell B","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, et al.. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023, 22:268-82. 10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325121","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","author":"Banks SA","year":"2020","unstructured":"Banks SA, Morris PP, Chen JJ, et al.. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. 2020, 10.1136\/jnnp-2020-325121","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram A","year":"2019","unstructured":"Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol. 2019, 266:2481-7. 10.1007\/s00415-019-09440-8","journal-title":"J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2023.07.002","article-title":"Fulminant anti-myelin oligodendrocyte glycoprotein-associated cerebral cortical encephalitis: case series of a severe pediatric myelin oligodendrocyte glycoprotein antibody-associated disease phenotype","volume":"147","author":"Kannan V","year":"2023","unstructured":"Kannan V, Sandweiss AJ, Erickson TA, et al.. Fulminant anti-myelin oligodendrocyte glycoprotein-associated cerebral cortical encephalitis: case series of a severe pediatric myelin oligodendrocyte glycoprotein antibody-associated disease phenotype. Pediatr Neurol. 2023, 147:36-43. 10.1016\/j.pediatrneurol.2023.07.002","journal-title":"Pediatr Neurol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius S","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, et al.. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018, 15:134. 10.1186\/s12974-018-1144-2","journal-title":"J Neuroinflammation"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters PJ","year":"2019","unstructured":"Waters PJ, Komorowski L, Woodhall M, et al.. A multicenter comparison of MOG-IgG cell-based assays. Neurology. 2019, 92:e1250-5. 10.1212\/WNL.0000000000007096","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211022767","article-title":"Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients","volume":"7","author":"Held F","year":"2021","unstructured":"Held F, Kalluri SR, Berthele A, Klein AK, Reindl M, Hemmer B. Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients. Mult Scler J Exp Transl Clin. 2021, 7:20552173211022767. 10.1177\/20552173211022767","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000011","article-title":"AQP4 autoantibody assay performance in clinical laboratory service","volume":"1","author":"Fryer JP","year":"2014","unstructured":"Fryer JP, Lennon VA, Pittock SJ, et al.. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm. 2014, 1:e11. 10.1212\/NXI.0000000000000011","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102638","article-title":"Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder","volume":"47","author":"Sechi E","year":"2021","unstructured":"Sechi E, Buciuc M, Flanagan EP, et al.. Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Mult Scler Relat Disord. 2021, 47:102638. 10.1016\/j.msard.2020.102638","journal-title":"Mult Scler Relat Disord"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1:\u00a0results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius S","year":"2020","unstructured":"Jarius S, Pellkofer H, Siebert N, et al.. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1:\u00a0results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation. 2020, 17:261. 10.1186\/s12974-020-01824-2","journal-title":"J Neuroinflammation"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier R","year":"2021","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A, et al.. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021, 20:762-72. 10.1016\/S1474-4422(21)00218-0","journal-title":"Lancet Neurol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.44.1.1","article-title":"Megadose corticosteroids in multiple sclerosis","volume":"44","author":"Kupersmith MJ","year":"1994","unstructured":"Kupersmith MJ, Kaufman D, Paty DW, et al.. Megadose corticosteroids in multiple sclerosis. Neurology. 1994, 44:1-4. 10.1212\/wnl.44.1.1","journal-title":"Neurology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7540.525","article-title":"Diagnosis and treatment of multiple sclerosis","volume":"332","author":"Murray TJ","year":"2006","unstructured":"Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ. 2006, 332:525-7. 10.1136\/bmj.332.7540.525","journal-title":"BMJ"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG antibody associated central nervous system demyelination","volume":"11","author":"Weber MS","year":"2018","unstructured":"Weber MS, Derfuss T, Metz I, Br\u00fcck W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord. 2018, 11:1756286418762083. 10.1177\/1756286418762083","journal-title":"Ther Adv Neurol Disord"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid SH","year":"2018","unstructured":"Hamid SH, Whittam D, Saviour M, et al.. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol. 2018, 75:65-71. 10.1001\/jamaneurol.2017.3196","journal-title":"JAMA Neurol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.04.021","article-title":"Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease","volume":"32","author":"Tsantes E","year":"2019","unstructured":"Tsantes E, Curti E, Siena E, Granella F. Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease. Mult Scler Relat Disord. 2019, 32:27-9. 10.1016\/j.msard.2019.04.021","journal-title":"Mult Scler Relat Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/215838-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T15:18:23Z","timestamp":1709738303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/215838-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.55652","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}